GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Enterprise Value

Telo Genomics (TSXV:TELO) Enterprise Value : C$6.24 Mil (As of May. 08, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Telo Genomics's Enterprise Value is C$6.24 Mil. Telo Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was C$-2.38 Mil. Therefore, Telo Genomics's EV-to-EBIT ratio for today is -2.62.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Telo Genomics's Enterprise Value is C$6.24 Mil. Telo Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was C$-2.35 Mil. Therefore, Telo Genomics's EV-to-EBITDA ratio for today is -2.65.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Telo Genomics's Enterprise Value is C$6.24 Mil. Telo Genomics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil. Therefore, Telo Genomics's EV-to-Revenue ratio for today is .

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Telo Genomics's Enterprise Value is C$6.24 Mil. Telo Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was C$-1.96 Mil. Therefore, Telo Genomics's EV-to-FCF ratio for today is -3.18.


Telo Genomics Enterprise Value Historical Data

The historical data trend for Telo Genomics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Enterprise Value Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.03 24.17 18.59 18.35 13.00

Telo Genomics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.00 7.51 13.00 10.86 10.75

Competitive Comparison of Telo Genomics's Enterprise Value

For the Diagnostics & Research subindustry, Telo Genomics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Enterprise Value falls into.


;
;

Telo Genomics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Telo Genomics's Enterprise Value for the fiscal year that ended in Jun. 2024 is calculated as

Telo Genomics's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (TSXV:TELO) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Telo Genomics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6.239/-2.382
=-2.62

Telo Genomics's current Enterprise Value is C$6.24 Mil.
Telo Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.38 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Telo Genomics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=6.239/-2.354
=-2.65

Telo Genomics's current Enterprise Value is C$6.24 Mil.
Telo Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.35 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Telo Genomics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.239/0
=

Telo Genomics's current Enterprise Value is C$6.24 Mil.
Telo Genomics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Telo Genomics's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.239/-1.96
=-3.18

Telo Genomics's current Enterprise Value is C$6.24 Mil.
Telo Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Executives
Kristan Joseph Weinberg Senior Officer
William John Meekison Director
Hugh Rogers Director

Telo Genomics Headlines

From GuruFocus